Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 57(22): 9435-46, 2014 Nov 26.
Article in English | MEDLINE | ID: mdl-25358084

ABSTRACT

Human carbonic anhydrase IX (CA IX) is highly expressed in tumor tissues, and its selective inhibition provides a potential target for the treatment of numerous cancers. Development of potent, highly selective inhibitors against this target remains an unmet need in anticancer therapeutics. A series of fluorinated benzenesulfonamides with substituents on the benzene ring was designed and synthesized. Several of these exhibited a highly potent and selective inhibition profile against CA IX. Three fluorine atoms significantly increased the affinity by withdrawing electrons and lowering the pKa of the benzenesulfonamide group. The bulky ortho substituents, such as cyclooctyl or even cyclododecyl groups, fit into the hydrophobic pocket in the active site of CA IX but not CA II, as shown by the compound's co-crystal structure with chimeric CA IX. The strongest inhibitor of recombinant human CA IX's catalytic domain in human cells achieved an affinity of 50 pM. However, the high affinity diminished the selectivity. The most selective compound for CA IX exhibited 10 nM affinity. The compound that showed the best balance between affinity and selectivity bound with 1 nM affinity. The inhibitors described in this work provide the basis for novel anticancer therapeutics targeting CA IX.


Subject(s)
Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrases/chemistry , Drug Design , Benzene/chemistry , Calorimetry , Carbon Dioxide/chemistry , Carbonic Anhydrase IV/chemistry , Catalysis , Catalytic Domain , Crystallization , Crystallography, X-Ray , Humans , Hydrogen-Ion Concentration , Kinetics , Neoplasms/drug therapy , Protein Binding , Protein Conformation , Recombinant Proteins/chemistry , Sulfonamides/chemistry , Thermodynamics
SELECTION OF CITATIONS
SEARCH DETAIL
...